Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab, chemotherapy, and apatinib in advanced EP-NEC
NCT05142865Phase 2Unknown
- Sponsor
- Huazhong University of Science and Technology
- Start
- Jan 2022
- Primary completion
- Jan 2024
- Modality
- Small Molecules, Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label trial of camrelizumab and Rivoceranib in extrapulmonary neuroendocrine carcinoma (EPNEC), sponsored by Huazhong University of Science and Technology. Status: unknown.
02
Drugs
camrelizumabRivoceranib
03
Conditions
extrapulmonary neuroendocrine carcinoma (EPNEC)
Beyond the preview
Go deeper on NCT05142865.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05142865.